Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Therapy Directory

Tirzepatide clinical trials

Directory of U.S. ClinicalTrials.gov public records that list Tirzepatide as a study intervention. Browse Tirzepatide recruiting trials, filter by phase, sponsor, or location, and open the official ClinicalTrials.gov study record for each result.

ClinicalTrials.gov public records Last synced May 21, 2026, 12:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
80
Shown on this page
12
Local indexed summaries
80
Local recruiting
31
The trial list below is retrieved from the live ClinicalTrials.gov search API for Tirzepatide. Results on this page are currently sorted by Recently updated.

Filter and sort this therapy

These controls apply only within Tirzepatide. Default order is Recently updated. Add condition, location, sponsor, or recruitment status to narrow this therapy page further.

Reset therapy filters
Clear filters
Showing 1–12 of 80 matching trials for Tirzepatide.
Indexed local directory records.

Top conditions

Obesity 30 Overweight 14 Type 2 Diabetes 12 Endometrial Cancer 3 Obesity and Overweight 3 Type 2 Diabetes Mellitus 3

Top sponsors

Eli Lilly and Company 30 Brigham and Women's Hospital 7 Novo Nordisk A/S 4 Massachusetts General Hospital 2 Mayo Clinic 2 National Institute on Alcohol Abuse and Alcoholism (NIAAA) 2

Top locations

Houston, Texas 21 Dallas, Texas 20 Chicago, Illinois 18 Miami, Florida 17 San Antonio, Texas 16 Jacksonville, Florida 14

Indexed official records

Open in full search
Recruiting Phase 1 Interventional

Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD)

NCT07559500
View directory record Official record
Conditions
Alcohol Use Disorder (AUD)
Interventions
Placebo, Tirzepatide, [11C]NNC-112, [11C]raclopride plus drug
Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
21 Years to 65 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced May 21, 2026, 12:34 AM EDT
Recruiting Phase 3 Interventional

Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight

NCT06937099
View directory record Official record
Conditions
Crohn's Disease, Obesity or Overweight
Interventions
Mirikizumab, Placebo, Tirzepatide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
290 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
35
States / cities
Dothan, Alabama • Anaheim, California • Beverly Hills, California + 29 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced May 20, 2026, 11:56 PM EDT
Recruiting Phase 3 Interventional

A Study of Tirzepatide in Adolescents With Obesity and Weight-Related Comorbidities (SURMOUNT-ADOLESCENTS-2)

NCT06439277
View directory record Official record
Conditions
Obesity, Weight Gain
Interventions
Placebo, Tirzepatide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years to 17 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
15
States / cities
Los Angeles, California • Sacramento, California • Wilmington, Delaware + 12 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced May 20, 2026, 6:26 AM EDT
Recruiting Phase 3 Interventional

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

NCT07165028
View directory record Official record
Conditions
Metabolic Dysfunction-Associated Steatotic Liver Disease
Interventions
Placebo, Retatrutide, Tirzepatide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
4,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
140
States / cities
Tuscaloosa, Alabama • Chandler, Arizona • Gilbert, Arizona + 122 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced May 20, 2026, 11:20 AM EDT
Recruiting Phase 4 Interventional

A Study to Investigate the Effectiveness of Tirzepatide (LY3298176) Following Initiation of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque PsO and Obesity or Overweight in Clinical Practice (TOGETHER AMPLIFY-PsO)

NCT06857942
View directory record Official record
Conditions
Overweight or Obesity, Psoriasis
Interventions
Tirzepatide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
40
States / cities
Phoenix, Arizona • Fountain Valley, California • Fremont, California + 36 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced May 18, 2026, 12:15 PM EDT
Recruiting Phase 4 Interventional

2024 Tirzepatide-Bariatric Surgery

NCT06721507
View directory record Official record
Conditions
Bariatric Surgery, Obesity and Obesity-related Medical Conditions
Interventions
Standard of Care, tirzepatide
Behavioral · Drug
Lead sponsor
Marlene Starr
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced May 17, 2026, 1:53 AM EDT
Recruiting Phase 2 Interventional

Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder

NCT06651177
View directory record Official record
Conditions
Opioid Use Disorder, Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe
Interventions
Placebo, Tirzepatide
Other · Drug
Lead sponsor
T. John Winhusen, PhD
Other
Eligibility
18 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
10
States / cities
Tarzana, California • Jacksonville, Florida • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced May 20, 2026, 8:43 AM EDT
Recruiting Phase 2 Interventional

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

NCT06143956
View directory record Official record
Conditions
Obesity, Overweight
Interventions
LY3305677, LY3532226, LY3549492, LY3841136, Placebo, Tirzepatide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,481 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
49
States / cities
Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 44 more
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced May 18, 2026, 11:13 AM EDT
Recruiting Phase 3 Interventional

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

NCT06937086
View directory record Official record
Conditions
Obesity or Overweight, Ulcerative Colitis
Interventions
Mirikizumab, Placebo, Tirzepatide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
37
States / cities
Dothan, Alabama • Anaheim, California • Beverly Hills, California + 30 more
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced May 20, 2026, 10:24 AM EDT
Recruiting Early Phase 1 Interventional

Tirzepatide in Obesity-Driven Endometrial Cancer

NCT07065552
View directory record Official record
Conditions
Endometrial Cancer, Obesity
Interventions
Tirzepatide
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced May 11, 2026, 9:28 PM EDT
Recruiting Phase 2 Interventional

Resistance Exercise and Incretin Mimetic for Cardiometabolic Health in Survivors of ALL With Obesity

NCT07228741
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Obesity
Interventions
Lifestyle Counseling, Resistance Exercise, Tirzepatide
Behavioral · Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced May 17, 2026, 1:47 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide

NCT06657209
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2, Pre Diabetes, Type 2 Diabetes
Interventions
1H-MRS, DXA scan, Fat biopsy, Insulin resistance testing, MRI, OGTT, Pioglitazone, Tirzepatide
Procedure · Radiation · Drug
Lead sponsor
Stanford University
Other
Eligibility
30 Years to 70 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
2
States / cities
Palo Alto, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced May 20, 2026, 2:20 AM EDT

About this Tirzepatide clinical trials directory page

What this page lists
U.S. ClinicalTrials.gov public records that list Tirzepatide as a study intervention, including recruiting, not yet recruiting, and active not recruiting trials.
How to narrow results
Use the filters above to scope by condition, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Tirzepatide.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, ranking of trials by quality, or AI-generated medical summaries.

Related: all therapy pages, browse by condition, browse by U.S. city, browse by sponsor, or open the full search for Tirzepatide.